|Title:||Method for preparing crystalline hydrate of oral celphalosporin and its composition|
|Abstract:||An antibacterial, 7.beta.-[(Z)-2-(2-aminothiazol-4-yl)-4-carboxybut-2-enoylamino]-3-cephem-4 -carboxylic acid is stable in a (di or tri)-hydrate crystal form. A pharmacologically effective amount of this hydrate is filled in a gelatin hard capsule and sealed by a band of gelatin to make a stable composition for clinical use after storage for a long time.|
|Inventor(s):||Hamashima; Yoshio (Kyoto, JP), Minami; Kyoji (Nara, JP), Kawata; Kyozo (Osaka, JP), Sakamoto; Teruo (Osaka, JP), Takeda; Toyohiko (Hyogo, JP), Suzuki; Yusuke (Osaka, JP), Tujikawa; Masanori (Nara, JP)|
|Assignee:||Shionogi & Co., Ltd. (Osaka, JP)|
|Filing Date:||Nov 21, 1988|
|Claims:||1. A process for the preparation of a crystalline hydrate of 7-.beta.-[(Z)-2-(2-aminothiazol-4-yl)-4-carboxybut-2-enoylamino]-3-cephem- 4-carboxylic acid having the X-ray diffraction pattern as follows: |
which comprises dissolving 7.beta.-[(Z)-2-(2-aminothiazol-4-yl)-4-carboxybut-2-enoylamino]-3-cephem-4 -carboxylic acid in aqueous acid, raising the pH of the solution to about 1.5 to 5 at about room temperature to form crystals, separating the wet crystals and drying the crystals until the first inflection point of the time versus outlet air temperature curve or the time versus outlet air humidity curve is reached to give the trihydrate or until the second inflection point of the same to give the dihydrate.
2. A process as claimed in claim 1 wherein the drying is carried out by stationary, through flow, circulation, or fluidized bed drying in an inert gas at relative humidity of not lower than 15% at 0.degree. to 60.degree. C.
3. A process as claimed in claim 1 wherein the drying is carried out with a through flow dryer using air of relative humidity 50 to 60% at 25.degree. to 40.degree. C.
4. A process as claimed in claim 1 wherein the drying is carried out with a fluidized bed dryer using air of relative humidity 50% to 60% at 10.degree. to 35.degree. C.
5. A process as claimed in claim 1 wherein the wet crystals are prepared by raising pH of an aqueous acid solution of the compound for crystallization and by ripening of crystals.
6. A process as claimed in claim 5 wherein concentration of the starting material in the aqueous acid solution is between 2.0 and 15.0%.
7. A process as claimed in claim 5 wherein the raising pH of the aqueous acid solution is effected with triethylamine, ammonium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, or anion exchange resins or by dilution with water.
8. A process as claimed in claim 5 wherein the ripening of crystals is continued for 10 minutes to 50 hours at 0.degree. to 70.degree. C.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.